Summary
• Phio Pharmaceuticals Corp. (PHIO) fell 7.2% in after-hours trading, decreasing to $1.16.
• The company presented its INTASYL® siRNA drug technology at the Advanced Therapies USA 2025 Congress, generating investor interest.
• Recent insider purchases by CEO Robert J. Bitterman suggest confidence, despite a challenging market environment and a significant stock decline.
PHIO Pharmaceuticals Corp. (NASDAQ: PHIO) is experiencing an after-hours decline of 7.2%, trading at $1.16 compared to its last close of $1.25. The stock’s movement comes without a defined catalyst.
Recent Presentation Opportunity Highlights Pipeline Potential
On November 17, Phio Pharmaceuticals announced a podium presentation focusing on its INTASYL® siRNA drug technology at the Advanced Therapies USA 2025 Congress, held from November 18-19. The congress provides a platform for showcasing their innovative cancer elimination strategies. This announcement has likely contributed to the ongoing investor interest, despite the company’s current stock movement.
Financial Performance Overview
In its latest reported quarter, Phio Pharmaceuticals posted a net loss of $0.44 per share, slightly surpassing the consensus estimate of a $0.45 loss. The company’s performance reflects a surprise of 2.2% when compared to analysts’ expectations. They also recently reported advancements in clinical trials for skin cancer treatments, including favorable pathology results at increased dosage levels.
Insider Activity Spotlight
Recent insider transactions revealed that Robert J. Bitterman, the Chairman, President, and CEO, conducted personal purchases of the company’s shares. On November 21, he acquired 5,000 shares at $1.14 each. This followed a prior purchase of an equal number of shares at $1.27 on November 18. Such insider buying could signal confidence in the company’s ongoing projects, although the market reaction remains tepid.
Market and Technical Review
Currently, PHIO’s stock is facing a challenging trading environment, with an RSI of 22.08 indicating an oversold condition. The stock has seen significant volatility, exhibiting a weekly performance dip of nearly 24%. Compared to its average trading volume, which has been approximately 2.7 million over the last three months, the current volume of 143,750 shares traded appears relatively low.
With the latest update now reflected in trading, investors are closely watching how the stock’s volume and momentum develop in the next session.